Horizon Pharma Reports Clinical Data on RAYOS Tablets Which Will Be Presented at American College of Rheumatology Annual Meeting

Horizon Pharma, Inc HZNP today announced that two published abstracts of its approved treatment RAYOS(R) (prednisone) delayed-release tablets will be presented during the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting, October 25-30, 2013 in San Diego, CA. RAYOS Abstracts to be Presented -- Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year -- Lead Author: Frank Buttgereit, M.D., Senior Consultant and Deputy Head of the Department of Rheumatology and Clinical Immunology, Charite Hospital, Berlin -- Session: Rheumatoid Arthritis - Clinical Aspects Poster III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis -- Tuesday, October 29, 2013: 8:30 AM-4:00 PM -- Presentation Number: 2255 -- https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/32990 -- Switching From Immediate Release (IR) Prednisone to Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) -- Lead Author: Rieke Alten, M.D., Chief of the Internal Medicine Division, Schlosspark Clinic, Berlin -- Session: Rheumatoid Arthritis - Clinical Aspects Poster III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis -- Tuesday, October 29, 2013: 8:30 AM-4:00 PM -- Presentation Number: 2265 -- https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/34567